The Global Antibody-drug Conjugates Market is poised to value USD 16820.81 million by 2028 end at a CAGR of 16.4% during the forecast period 2022 to 2028.
Conjugation is the covalent bonding of prodrugs or drugs to natural or synthetic molecule carriers for targeted use, such as polypeptides or proteins, lipids, polymers, and carbohydrates. Conjugation has evolved into an important tool for drug release and targeted drug delivery of tiny molecules and biotherapeutic modalities such as protein-drug conjugation, antibody-drug conjugation, polymer-drug conjugation, and T-cell dual affinity re-targeting conjugation. Drug conjugation can improve pharmacokinetics, drug stability, and pharmacodynamic properties while also changing toxicity profiles. Antibody-drug conjugates (ADCs) are a type of biopharmaceutical drug that is designed to treat and cure cancer. In contrast to chemotherapy, ADCs are used to target and destroy tumour cells while leaving healthy cells alone. The vast majority of approved ADCs are used to treat breast cancer patients. Age, obesity, risky alcohol use, a family history of breast cancer, a history of radiation exposure, reproductive history (first menstrual cycle age and first pregnancy age), and tobacco use are all risk factors for breast cancer. According to the American Cancer Society’s cancer statistics, breast cancer has the highest incidence and the second-highest overall mortality rate among women in the United States. Because of their various mechanisms of action, such as natural properties, engagement of cytotoxic T cells, and delivery of cytotoxic payloads, the demand for various antibody-based cancer therapies is increasing. According to an article published in the Antibody-drug Society, immune checkpoint modulators, antibody-drug conjugates (ADCs), and bispecific antibodies are increasingly dominating the commercial clinical pipeline of cancer therapies. Antibody-drug conjugates (ADCs) account for roughly 20% of the clinical pipeline of cancer antibodies. To obtain FDA approval to commercialise a new prescription drug, a pharmaceutical company must go through five steps: discovery/concept, preclinical research, clinical research, FDA review, and FDA post-market safety monitoring. According to the FDA Review Project, the FDA approval process for drugs (9 to 12 years) and devices is complex and time-consuming (7 years). ADCs have a manageable side-effect profile due to their high selectivity, with nausea and vomiting being the most common toxicities. This, however, varies depending on the ADC and the associated payload. Other side effects include fever, nausea, infection, vomiting, and stomatitis. Low blood counts, liver damage, including hepatic veno-occlusive disease, infusion-related reactions (IRRs), and bleeding are among the serious side effects.
The astute research report on Antibody-drug Conjugates market provides intricate details for analyzing appropriate parameters and valuable insights. The report offers extensive information about this business to help bring forth the growth potential of the market across various segments and provides the clients with a comprehensive analysis of factors like market size, market growth trends, competitive landscape, product utilization, regional growth prospects, and application potential, etc. The data provided in the report has been gathered from a wide variety of sources by using primary and secondary research. This Antibody-drug Conjugates research report also provides crucial insights into consumer behaviour, brand positioning, pricing analysis, and key player strategies. The market overview included in the Antibody-drug Conjugates research report incorporates critical factors procured from industry analysts, prominent players as well as trade and industrial organizations.
The report on Antibody-drug Conjugates market offers up-to-date information on the factors impeding the market growth which shall provide vendors with crucial insights into understanding the market dynamics thereby aiding the clients to sketch out a better business strategy. These factors will help them identify market growth opportunities. Furthermore, FutureWise research analysts provide timely assistance to their customers in understanding eccentric market parameters more effectively thereby leading to better decision-making.
Get a Sample of the Antibody-drug Conjugates Market Report @ https://www.futurewiseresearch.com/request-sample.aspx?id=10000&page=requestsample
The Antibody-drug Conjugates market research report is segmented – by technology, by application, and by region. It also consists of insights regarding the revenue value and sales volume during the forecasted timeframe of 2022 to 2028.
Antibody-drug Conjugates Market Segmentation:
By Technology
Cleavable Linker
Non-cleavable Linker
By Application
Blood Cancer
Breast Cancer
Ovarian Cancer
Lung Cancer
Brain Tumour
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East and Africa
Antibody-drug Conjugates Market Regional Analysis:
The report provides a complete evaluation of the potential amplification of the Antibody-drug Conjugates Market in pivotal geographic regions such as North America, Asia Pacific, Europe, Latin America and Middle East & Africa.
Competitive Landscape:
Some of the key market players are
F. Hoffmann-La Roche Ltd
Seattle Genetics, Inc.
Pfizer Inc.
Takeda Pharmaceutical Company Limited
AbbVie Inc
Immunomedics
Novartis AG
Genentech Inc.
Immunogen Inc.
Progenics Pharmaceuticals
Bayer Healthcare Pharmaceuticals
Agensys Inc.
Concortis Biotherpautics
Sanofi S.A.
Celldex Therapeutics Inc.
FutureWise Key Takeaways:
Growth prospects
SWOT analysis
Key market trends
Key data-points affecting market growth
Objectives of the Study:
To provide an extensive analysis of the global Antibody-drug Conjugates market by technology, by application, and by region
To carter complex data and information on the characteristics influencing the market growth (drivers, restraints, opportunities, and industry-specific restraints)
To predict and assess micro-markets and the overall market
To anticipate the market size, in key geographical regions (along with countries)— North America, Europe, Asia Pacific, Latin America and the Middle East and Africa
To estimate and inspect competitive landscape mapping- technological advancements, product launches, mergers and expansions
Flexible Delivery Model:
Our delivery model is flexible, so you can suggest changes to the content/scope as per your requirement
With purchase of any license of the report the customization Mobility Care offered is free of charge
You can directly forward your requirements/changes to the current table of content to: sales@futurewiseresearch.com
About FutureWise Market Research:
We specialize in high-growth niche market research, offering flexibility, agility, and customized solutions for our clients. By providing our clients with market insights and consulting services, we ensure they stay on top of their industries for years to come.
FutureWise Market Research
Vinay T – Head of Business Development
Email: sales@futurewiseresearch.com
UK: +44 141 628 9353 | USA: +1 347 709 4931
Website: www.futurewiseresearch.com
